UPCOMING SESSIONS in ET
Mon, Apr 20, 2026
10:00 – 11:00 PM UTC
Dr. Tanmeet Sethi - From Surviving to Thriving: Reclaiming Joy with Chronic Illness Tanmeet Sethi MD Click To Register
UPCOMING SESSIONS in ET
Mon, Apr 20, 2026 · 10:00 – 11:00 PM UTC
Dr. Tanmeet Sethi - From Surviving to Thriving: Reclaiming Joy with Chronic Illness
Tanmeet Sethi MD
Click To Register
View all sessions

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Published: Mar 30, 2026
Category
Clinical Trials and Research
Source
IMMIX BIOPHARMA

LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that NEXICART-2 enrollment is complete, meeting Company guidance, with topline results expected in Q3 2026, followed by BLA submission and planned commercial launch.

News Url
Read More